Most episodes of short-term symptomatic hypoglycemia are effectively treated by the ingestion of carbohydrates 1) or glucagon injection.
glutamine, 15) 4) L-alanine from glutamine dipeptide catabolism stimulates the release of glucagon. 16, 17) In addition the contribution of the liver gluconeogenesis from glutamine dipeptide and their metabolites L-alanine and L-glutamine to prevent prolonged hypoglycemia were investigated. Animals Adult male Wistar rats (180-220 g) were maintained on food and water ad libitum before the initiation of experimental procedures. The manipulation of the animals was approved by the ethical committee of the State University of Maringá, PR, Brazil (approval number 042/2006). On the day before the experiment the animals were food deprived from 5:00 p.m. All experiments were performed with overnight fasted rats (5:00 p.m.-9:00 a.m.).
MATERIALS AND METHODS

Materials
Experimental Prolonged IIH A preliminary experiment to characterize the prolonged IIH after an intraperitoneal (i.p.) injection of Detemir insulin (1.0 U/kg) was done. Detemir insulin was not diluted but intraperitoneally injected (9:00 a.m.) with help of an infusion pump (Insight ® 4Ϯ4 .0 mg/dl, 28.1Ϯ2.5 mg/dl, 44.9Ϯ7.6 mg/dl, 68.2Ϯ6.6 mg/dl, and 73.2Ϯ1.2 mg/dl, respectively. From these data, we observed that glycemia decreased until 4 h after insulin injection (phase of decreasing glycemia) and then progressively increased (phase of glycemia recovery). Thus, to verify whether oral glutamine dipeptide promotes glycemia prevention, this substance was administered immediately after insulin injection and glycemia values were measured 4 h later, when the lowest value of glycemia was obtained.
Effect of Oral (Gavave) Administration of Glutamine Dipeptide in the Prevention of Prolonged IIH The rats were killed by decapitation 4 h after simultaneous i.p. Detemir insulin injection plus oral glutamine dipeptide (0, 1.56, 3.12, 6.25, 12.5, 25.0, 50.0, 100.0 mg/kg) and the blood was collected for serum glucose analysis. 18) Liver Perfusion Experiments The rats were anaesthetized with an i.p. injection of sodium thiopental (40 mg/kg) and submitted to laparotomy. The livers were perfused in situ according to the protocol illustrated in the Figs. 1 and 2, in which after a pre-perfusion period (10 min), the gluconeogenic substrate was dissolved in the perfusion fluid, followed by a post-infusion period (10 min) to allow the return to basal levels. Samples of the effluent perfusion fluid were collected at 5-min intervals and the level of glucose 18) and urea 19) were analyzed. The differences in the glucose and urea production during and before the infusion of the glucoenogenic substrate permitted to calculate the area under the curves (AUC ).
In the first set of experiments the glucose production from livers of rats that received an i.p. saline (normoglycemic rats) or i.p. Detemir insulin (hypoglycemic rats) were compared ( Fig. 1) .
In the second set of experiments livers from rats which received i.p. Detemir insulin (hypoglycemic rats) were infused with increasing concentrations of L-alanine, L-glutamine or glutamine dipeptide. Thus, the values of AUC shown in Figs. 3-5 were obtained by the difference between the glucose and urea production during and before the infusion of the gluconeogenic substrates, as illustrated in Fig. 2A .
In the third set of experiments livers from rats which received i.p. Detemir insulin (hypoglycemic rats) were infused with L-lactate (3 mM) plus increasing concentrations of NH 4 Cl. Thus, the values of AUC shown in Fig. 6 were obtained by the difference between the glucose and urea production during the infusion of L-lactate plus NH 4 Table 1 the hypoglycemia obtained 4 h after insulin injection was partially prevented with oral administration of glutamine dipeptide, since the values of glycemia increased (pϽ0.05) from 1.56 until 12.5 mg/kg (1.56, 3.12, 6.25, 12.5 mg/kg). On the other hand, from 12.5 mg/kg (25.0, 50.0, 100.0 mg/kg), the values of glycemia decreased (pϽ0.05).
RESULTS
Effect of Oral Glutamine Dipeptide on Glycemia at 4 h after Insulin Administration As shown by
Liver Perfusion Experiments In the first set of experiments livers from rats that received an i.p. saline (normoglycemic rats) or i.p. Detemir insulin (hypoglycemic rats) were infused with glutamine dipeptide (5 mM). Livers from hypoglycemic rats showed higher ( pϽ0.05) glucose production than livers of normoglycemic rats (Fig. 1) .
In the second set of experiments livers from rats which received i.p. Detemir insulin (hypoglycemic rats) were infused with increasing concentrations of L-alanine, L-glutamine or glutamine dipeptide. The maximal hepatic glucose production to L-alanine (Fig. 3A) , L-glutamine (Fig. 4A ) and glutamine dipeptide (Fig. 5A) were obtained with 5.0 mM. From this value, the hepatic glucose production from L-alanine (Fig. 3A) or L-glutamine (Fig. 4A) decreased (pϽ0.05) . However, to glutamine dipeptide the glucose production was maintained (Fig. 5A) . On the other hand the urea production from L-alanine (Fig. 3B) , L-glutamine (Fig. 4B ) and glutamine dipeptide (Fig. 5B) did not decrease after getting the maximal value. The livers were perfused as described in Materials and Methods. The AUCϭareas under the curves (mmol/g) were obtained as described in Fig The livers were perfused as described in Materials and Methods. The AUCϭareas under the curves (mmol/g) were obtained as described in Fig In the third set of experiments livers from rats which received i.p. Detemir insulin (hypoglycemic rats) were infused with L-lactate (3 mM) plus increasing concentrations of NH 4 Cl (0.015, 0.031, 0.062, 0.125 mM). Thus, livers from IIH rats that received increasing concentrations of ammonia showed increasing values of urea production (Fig. 6B) . On the other hand, the glucose production from L-lactate (Fig.  6A ) decreased (pϽ0.05) in the presence of NH 4 Cl (from 0.062 mM).
DISCUSSION
Our previous study 9) demonstrated that the blood concentrations of L-alanine and L-glutamine were decreased during long term IIH. In agreement with this study, 9) we also demonstrated that oral glutamine dipeptide was able to promote glycemia recovery during long term IIH.
11) Therefore, we expanded these previous studies investigating if glutamine dipeptide could prevent or decrease the intensity of prolonged IIH.
As shown by Table 1 , the oral administration of glutamine dipeptide partially protects against prolonged hypoglycaemia and the dose of 12.5 mg/kg represents the best result.
To investigate the participation of the hepatic gluconeogenesis in the protective effect of glutamine dipeptide against hypoglycemia, livers from rats submitted to prolonged IIH and normoglycemic rats were compared. The results demonstrated an increased (pϽ0.05) glucose production from glutamine dipeptide in livers from IIH rats. The mechanism involved in the increased hepatic capacity to produce glucose under prolonged IIH probably involves increased release of counterregulatory hormones, 20) which antagonise the effects of insulin on the key enzymes of gluconeogenesis. 21) Another mechanism involves a favorable potential redox for gluconeogenesis, i.e., an increased reduced nicotinamide adenine dinucleotide/oxidized form of nicotinamide adenine dinucleotide (NADH/NAD ϩ ) cytosolic ratio, inferred by the higher L-lactate/pyruvate ratio in livers from IIH rats. 8) Because it is hard to estimate exactly how much of the amount of L-alanine, L-glutamine and glutamine dipeptide actually entering in the liver, after the oral administration of glutamine dipeptide 15) the effect of the portal infusion of increasing concentrations of these substances on liver glucose production was investigated. Thus, from experiments employing increasing concentrations of L-alanine (Fig. 3A) , Lglutamine (Fig. 4A) or glutamine dipeptide (Fig. 5A) we observed that the increased availability of these gluconeogenic substrates also favored the liver glucose production and probably contributed to the hypoglycemia prevetion promoted by increasing doses of oral glutamine dipeptide (from the dose of 1.56 mg/kg until 12.5 mg/kg). However, after getting the maximal hepatic glucose production, which reflects the liver capacity to produce glucose from the saturating concentration of L-alanine (Fig. 3A) or L-glutamine (Fig. 4A ) the hepatic glucose production from these substances decreased (pϽ0.05) if a more elevated concentration was used. In contrast, the hepatic glucose production from glutamine dipeptide was maintained (Fig. 5A) .
Thus, a question can be raised: why the infusions of more elevated concentrations of L-alanine (Fig. 3A) , L-glutamine (Fig. 4A ), but not glutamine dipeptide (Fig. 5A) inhibited the liver gluconeogenesis? Before answering this question it is necessary to consider that the catabolism of amino acids generates ammonia which must be disposed of. 22) Therefore, if the glucose precursor is an amino acid, hepatic gluconeogenesis and ureagenesis, that share common intermediates, must be activated simultaneously. 23) In agreement with this point of view the production of urea also increased (pϽ0.05) during the infusion of increasing concentrations of L-alanine (Fig. 3B) , L-glutamine (Fig. 4B ) and glutamine dipeptide (Fig. 5B) . However, the excess intramitochondrial concentration of ammonia obtained with the infusion of more elevated concentrations of L-alanine or L-glutamine probably decrease the intermediates of the citric acid cycle leading to depletion of ATP 24) and consequently an inhibition of gluconeogenesis.
However, considering that glutamine dipeptide did not inhibit the hepatic glucose production, how can we explain the lower glycemia (pϽ0.05) with more elevated oral doses (from 12.5 mg/kg until 100 mg/kg) of glutamine dipeptide? Firstly, it is necessary to consider that the participation of liver gluconeogenesis is not the whole story since glutamine dipeptide is an important energetic fuel to extra-hepatic tissues, particularly to the kidneys where glutamine is the main gluconeogenic substrate. 12) Therefore, the possibility of the inhibition of liver gluconeogenesis by ammonia from the catabolism of glutamine dipeptide by extra-hepatic tissues must be considered. Thus, to investigate the participation of ammonia in the inhibition of gluconeogenesis, the hepatic capacity in producing glucose from L-lactate (3 mM) during the infusion of increasing concentrations of ammonia in livers from IIH rats were evaluated. The reason to use L-lactate as gluconeogenic substrate was based in the following facts: 1) the liver catabolism of Llactate does not produce ammonia; 2) L-lactate, which enters in the gluconeogenic pathway as pyruvate uses all steps of gluconeogenesis before producing glucose. Therefore, by using increasing concentration of ammonia we observed an inhibition of gluconeogenesis ( Fig. 6A) with lower concentration of ammonia than that which gets the maximal ureagenesis (Fig. 6B) .
Finally, the results shown here suggest that oral glutamine dipeptide could decrease the intensity of prolonged IIH. However, considering the possibility of the inhibition of liver gluconeogenesis and the reduction of glycemia with more elevated doses of glutamine dipeptide, the applicability of these results, with particular focus on the oral administration of this substance awaits further experimental studies.
